Cargando…
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation
BACKGROUND: Atazanavir causes plasma indirect bilirubin to increase. We evaluated associations between Gilbert’s polymorphism and bilirubin-related atazanavir discontinuation stratified by race/ethnicity. PATIENTS AND METHODS: Patients had initiated atazanavir/ritonavir-containing regimens at an HIV...
Autores principales: | Leger, Paul, Chirwa, Sanika, Nwogu, Jacinta N., Turner, Megan, Richardson, Danielle M., Baker, Paxton, Leonard, Michael, Erdem, Husamettin, Olson, Lana, Haas, David W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726942/ https://www.ncbi.nlm.nih.gov/pubmed/29117017 http://dx.doi.org/10.1097/FPC.0000000000000316 |
Ejemplares similares
-
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano, Roberto, et al.
Publicado: (2013) -
External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012) -
Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
Publicado: (2013) -
Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia
por: Vardhanabhuti, Saran, et al.
Publicado: (2015) -
Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir
por: Cotter, Aoife G, et al.
Publicado: (2013)